Abstract
Central nervous system is not spared from the deleterious effects of diabetes, since several studies have described neuropsychological and neurobehavioral changes in diabetic subjects, suggesting that diabetic encephalopathy should be recognized as a complication of this complex metabolic disorder. In fact, psychiatric manifestations may accompany this encephalopathy, since the prevalence of depression in diabetic patients is much higher than in the general population. Furthermore, evidences from preclinical and clinical studies suggest that GABA plays a role both in the pathophysiology of the diabetic encephalopathy-related depression. So, this review addresses the GABAergic modulation in diabetic encephalopathy-related depression. Data presented from literature support the association between GABA and depressive- like behaviors in diabetic encephalopathy, being this neurotransmitter a potential target for the treatment of diabetes, depression and related comorbidities.
Keywords: Diabetes, depression, oxidative stress, GABA, clonazepam, insulin, pancreas.
Current Pharmaceutical Design
Title:GABAergic Modulation in Diabetic Encephalopathy-Related Depression
Volume: 21 Issue: 34
Author(s): Carlos Alberto Yasin Wayhs, Helena Maria Tannhauser Barros and Carmen Regla Vargas
Affiliation:
Keywords: Diabetes, depression, oxidative stress, GABA, clonazepam, insulin, pancreas.
Abstract: Central nervous system is not spared from the deleterious effects of diabetes, since several studies have described neuropsychological and neurobehavioral changes in diabetic subjects, suggesting that diabetic encephalopathy should be recognized as a complication of this complex metabolic disorder. In fact, psychiatric manifestations may accompany this encephalopathy, since the prevalence of depression in diabetic patients is much higher than in the general population. Furthermore, evidences from preclinical and clinical studies suggest that GABA plays a role both in the pathophysiology of the diabetic encephalopathy-related depression. So, this review addresses the GABAergic modulation in diabetic encephalopathy-related depression. Data presented from literature support the association between GABA and depressive- like behaviors in diabetic encephalopathy, being this neurotransmitter a potential target for the treatment of diabetes, depression and related comorbidities.
Export Options
About this article
Cite this article as:
Wayhs Alberto Yasin Carlos, Barros Maria Tannhauser Helena and Vargas Regla Carmen, GABAergic Modulation in Diabetic Encephalopathy-Related Depression, Current Pharmaceutical Design 2015; 21 (34) . https://dx.doi.org/10.2174/1381612821666150914121331
DOI https://dx.doi.org/10.2174/1381612821666150914121331 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Introduction to Molecular Modeling of G-Protein Coupled Receptors
Current Computer-Aided Drug Design Allosteric Modulators of GABAB Receptors: Mechanism of Action and Therapeutic Perspective
Current Neuropharmacology Endocannabinoids and Their Receptors: Physiology, Pathology and Pharmacology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Past, Present and Future of Antiepileptic Drug Therapy - Finding a Place for Heterocyclics
Mini-Reviews in Medicinal Chemistry Brain Permeable Nanoparticles
Recent Patents on CNS Drug Discovery (Discontinued) Bacopa monnieri Supplements Offset Paraquat-Induced Behavioral Phenotype and Brain Oxidative Pathways in Mice
Central Nervous System Agents in Medicinal Chemistry HIV-1 Reactivation Induced by Apicidin Involves Histone Modification in Latently Infected Cells
Current HIV Research An Emerging Antiarrhythmic Target: Late Sodium Current
Current Pharmaceutical Design Programming Apoptosis and Autophagy with Novel Approaches for Diabetes Mellitus
Current Neurovascular Research Persistent Current Blockers of Voltage-Gated Sodium Channels: A Clinical Opportunity for Controlling Metastatic Disease
Recent Patents on Anti-Cancer Drug Discovery The Intestinal Absorption Mechanism of Gabapentin Makes it Appropriate for Gastroretentive Delivery
Current Clinical Pharmacology Editorial [Hot Topic: The Pineal Hormone Melatonin in Health and Disease (Guest Editors: Charanjit Kaur)]
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Post-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management
Current Neuropharmacology Agonists and Antagonists of Metabotropic Glutamate Receptors: Anticonvulsants and Antiepileptogenic Agents?
Current Neuropharmacology The Effects of Psychological Stress on Depression
Current Neuropharmacology Neuroimaging methods in Epilepsy of Temporal Origin
Current Medical Imaging PET and SPECT Imaging of the NMDA Receptor System: An Overview of Radiotracer Development
Mini-Reviews in Medicinal Chemistry The Urokinase Receptor Interactome
Current Pharmaceutical Design Molecular Docking, Synthesis and CNS Activity of Some Novel 1, 4-Benzodiazepine Derivatives
Letters in Drug Design & Discovery Angiogenic and Vascular Modulation by Extracellular Matrix Cleavage Products
Current Pharmaceutical Design